More than 67,000 cases of Power Stick deodorant recalled nationwide
A.P. Deauville, a health and beauty product manufacturer in Pennsylvania, issued a recall for 67,214 cases of Power Stick roll-on deodorant on July 10. The products were recalled for cGMP deviations, which are deviations from established regulations outlined by the Food and Drug Administration (FDA)-enforced Current Good Manufacturing Practices.
The recall does not specify a remedy for consumers or which regulations were missed. A.P. Deauville did not immediately respond for comment about the recall when contacted by USA TODAY on Thursday, July 17.
What products are listed in the recall?
Can't see the table in your browser? Visit public.flourish.studio/visualisation/24285551/.
Where were the recalled products sold?
According to the recall, the Power Stick deodorants were sold nationwide. The deodorants are available for purchase from major retailers such as Walmart and Amazon.
What to do with the recalled Power Stick deodorant?
The FDA usually recommends discarding recalled products and contacting the manufacturer with any questions you may have.
Greta Cross is a national trending reporter at USA TODAY. Story idea? Email her at gcross@usatoday.com.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
42 minutes ago
- Newsweek
Potato Salad Recall Map Shows New Warning Issued in 5 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Hans Kissle is recalling its Red Potato Bliss Salad due to an undeclared wheat allergen discovered in a labeling error. Newsweek reached out to the company for comment via phone on Tuesday night and left a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential of damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. People with a wheat allergy could experience a "serious or life-threatening allergic reaction if they consume these products," the FDA warns. What To Know In the alert, the FDA says that 66 units of the potato salad are being recalled because of the mislabeling issue. The product is packaged in a 16-ounce container that is clear and has a white lid. The product's UPC Code number is 036217673706 and has a use-by date of August 20, 2025. The container says, "Hans Kissle Tri Color Twist Pasta Salad" while the top says, "Hans Kissle Red Bliss Potato Salad," the FDA says. There have been no reported illnesses or adverse reactions as it relates to this recall as of Tuesday, the FDA says. The recalled potato salads were distributed to Stop & Shop retail locations in five states, the alert notes. Below is a map showing the affected states, which include New York, New Jersey, Rhode Island, Connecticut and Massachusetts. What People Are Saying The FDA in the alert, in part: "The recall was initiated after it was discovered that 66 containers of Tricolor Twist Pasta Salad were mislabeled with the incorrect top label. While the front label correctly identifies the product, the top label misrepresents it as Red Bliss Potato Salad. The actual product contains wheat, which is not declared on the top label." In an email to Newsweek in January, the FDA said: "Most recalls in the U.S. are carried out voluntarily by the product manufacturer and when a company issues a public warning, typically via news release, to inform the public of a voluntary product recall, the FDA shares that release on our website as a public service. The FDA's role during a voluntary, firm-initiated, recall is to review the recall strategy, evaluate the health hazard presented by the product, monitor the recall, and as appropriate alert the public and other companies in the supply chain about the recall." It added: "The FDA provides public access to information on recalls by posting a listing of recalls according to their classification in the FDA Enforcement Report, including the specific action taken by the recalling company. The FDA Enforcement Report is designed to provide a public listing of products in the marketplace that are being recalled." Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts. What Happens Next Consumers are advised to return the recalled product to the original place of purchase for a full refund, the FDA says. People with additional questions may contact the company via phone at 978-556-4500 from 8 a.m. to 5 p.m. ET weekdays.
Business Upturn
2 hours ago
- Business Upturn
Respiree Secures Second FDA 510(k) Clearance, Expands Cardio-Respiratory Wearable to Home Use via 1Bio™ Connected Care Platform
By GlobeNewswire Published on August 6, 2025, 03:25 IST HOUSTON and SINGAPORE, Aug. 05, 2025 (GLOBE NEWSWIRE) — Respiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced it has received its second U.S. Food and Drug Administration (FDA) 510(k) clearance. The clearance expands the use of its RS001 cardio-respiratory wearable to home environments and includes approval for its connected care platform marketed as 1Bio™. Illustrative Image of Respiree's RS001 Wearable With its Connected Care 1Bio™ Platform The RS001 is a chest-worn device that directly measures respiration and offers passive cardio-respiratory monitoring. Originally cleared for in-patient clinical use, the RS001's use in home settings marks a significant step toward more accessible and preventive healthcare. The device connects to a cellular hub, which enables data to be visualized in real time via the connected care 1Bio™ dashboard. 'Respiration is the most predictive vital sign for clinical deterioration, yet it remains underutilized – particularly outside hospital settings,' said Dr. Gurpreet Singh, CEO and Founder of Respiree. 'This FDA 510(k) extension allows healthcare systems to passively and accurately monitor leading indicators in the home, enabling earlier interventions and reducing the overall burden on healthcare infrastructure.' The announcement follows Respiree's recent US$11.6 million Series A financing round, led by We Venture Capital and ClavystBio, which will accelerate development toward potential regulatory approvals and global market expansion. Respiree also announced plans to pursue additional FDA clearances for its proprietary AI software, aiming to integrate artificial intelligence models into the 1Bio™ platform for both inpatient and home-based care. 'These are exciting times for us,' added Dr. Singh. 'Our first 510(k) was for the wearable; this second one is for the platform. We are now focused on bringing our flagship AI models into the fold as a Software as a Medical Device (SaMD).' About Respiree Respiree™ is an AI/ML health tech company building state-of-the-art clinically-validated artificial intelligence (AI) for managing disease progression across healthcare's care continuum. The 1Bio™ platform by Respiree™ uses data from the EHR and its proprietary US-patented and FDA-cleared sensors to longitudinal measure and track disease progression. Respiree™ is now available in U.S., Australia and Asia-Pacific (APAC). Respiree™ is CE marked, has received regulatory clearances in Australia from the Therapeutics Goods Administration and has received the 510k clearance from the United States Food and Drug Administration (FDA). ( Media Enquiries Evangeline Fu Administrative Manager Respiree Pte Ltd Email: [email protected] A photo accompanying this announcement is available at Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
USA Today
2 hours ago
- USA Today
NFL reveals reasons why smelling salts are banned in 2025
The 2025 season will introduce some new rules and technology to the NFL, but one change in particular has upset one of the league's best tight ends. The San Francisco 49ers' George Kittle interrupted an interview on NFL Network to voice his displeasure over a new rule banning smelling salts. "I honestly just came up here to air a grievance," Kittle said during an episode of "Inside Training Camp Live" featuring teammate Fred Warner. "Our team got a memo today that smelling salts and ammonia packets were made illegal in the NFL. And I've been distraught all day." Kittle was especially upset because he uses smelling salts often during NFL games. "I'm an every drive guy," Kittle said. "I considered retirement. We got to figure out a middle ground here guys. Somebody help me out, somebody come up with a good idea... I miss those already." Jordan Addison suspension: Vikings WR gets three game ban, NFL announces Training camp scuffle: Baltimore Ravens and Indianapolis Colts get into joint practice brawl That's an under-the-radar change that will impact players across the league. USA TODAY Sports obtained the league memo and here's what the NFL told teams. NFL statement on smelling salts A league official confirmed to USA TODAY Sports that the teams are now prohibited from providing players smelling salts during games. The official declined to be identified because of the sensitivity of the matter. The memo that the NFL sent to teams today read: "In 2024, the FDA issued a warning to companies that produce commercially available ammonia inhalants (AIs), as well as to consumers about the purchase and use of AIs, regarding the lack of evidence supporting the safety or efficacy of AIs marketed for improving mental alertness or boosting energy. The FDA noted potential negative effects from AI use. AIs also have the potential to mask certain neurologic signs and symptoms, including some potential signs of concussion. As a result, the NFL Head, Neck, and Spine Committee recommended prohibiting the use of AIs for any purpose during play in the NFL. In light of this information, effective for the 2025 NFL season, clubs are prohibited from providing or supplying ammonia in any form at NFL games. For clarity, 'ammonia' refers to ammonia capsules, inhalers, ammonia in a cup, and any form of 'smelling salts.' This prohibition applies to all club personnel (including but not limited to team physicians, athletic trainers, strength and conditioning coaches and coaches or other personnel). The prohibition applies through the entirety of all NFL games, including during all pregame activities, and halftime, and applies on the sideline and in stadium locker rooms." NFL players have used smelling salts for years, and it isn't the first sport to ban them. Many boxing organizations banned them years ago because they can mask a severe injury.
